Group-based trajectory modeling to assess adherence to biologics among patients with psoriasis

ClinicoEconomics and Outcomes Research

Volumn 6, Issue 1, 2014, Pages 197-208

  Li, Yunfeng ^a   Zhou, Huanxue ^b   Cai, Beilei ^a   Kahler, Kristijan H ^a   Tian, Haijun ^a   Gabriel, Susan ^a   Arcona, Steve ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b KMK Consulting Inc   (United States)

Author keywords

Behavior; Classification; Dynamic; Grouping; Patterns; Proportion days of covered (PDC)

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; USTEKINUMAB;

ADULT; AGE; ANXIETY; ARTICLE; BIOLOGICAL THERAPY; COMORBIDITY; FEMALE; FOLLOW UP; GROUP BASED TRAJECTORY MODEL; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PREDICTION; PROPORTION OF DAYS COVERED; PSORIASIS; SEX DIFFERENCE; STATISTICAL MODEL;

EID: 84898432913     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S59339     Document Type: Article

References (29)

1. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-530.
2. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794-811.
3. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167(6):540-550.
4. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003. Available from: http://whqlibdoc.who.int/publications/2003/9241545992.pdf. Accessed August 2013.
5. Woltmann EM, Valenstein M, Welsh DE, etal. Using pharmacy data on partial adherence to inform clinical care of patients with serious mental illness. Psychiatr Serv. 2007;58(6):864-867.
6. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074-1090.
7. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3-12.
8. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care. 1988;26(8):814-823.
9. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105-116.
10. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7-8): 1280-1288.
11. Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109-138.
12. Nagin DS, Odgers CL. Group-based trajectory modeling (nearly) two decades later. J Quant Criminol. 2010;26(4):445-453.
13. Modi AC, Cassedy AE, Quittner AL, etal. Trajectories of adherence to airway clearance therapy for patients with cystic fibrosis. J Pediatr Psychol. 2010;35(9):1028-1037.
14. Franklin JM, Shrank WH, Pakes J, etal. Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence. Med Care. 2013;51(9):789-796.
15. Sandoval LF, Feldman SR. Biologics in practice: adherence to biologic therapy in psoriasis. The Dermatologist. 2013;21(2):30-34.
16. Degli Esposti L, Saragoni S, Batacchi P, etal. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. Clin Ther. 2012;34(1):190-199.
17. MarketScan® Research [database on the Internet]. Ann Arbor, MI: Truven Health Analytics; 2012. Available from: http://marketscan.truvenhealth.com/marketscanportal/. Accessed January 31, 2014.
18. Centers for Disease Control and Prevention [homepage on the Internet]. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Atlanta, GA: Centers for Disease Control and Prevention; 2014. Available from: http://www.cdc.gov/nchs/icd/icd9cm.htm. Accessed November 26, 2013.
19. Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res. 2001;29(3):374-393.
20. Nagin DS. Group-Based Modeling of Development. 1st ed. Cambridge, MA: Harvard University Press; 2005.
21. Schwarz G. Estimating the dimension of a model. Ann Stat. 1978;6(2): 461-464.
22. Kass RE, Raftery AE. Bayes Factors. J Am Stat Assoc. 1995;90(430): 773-795.
23. Neath AA, Cavanaugh JE. The Bayesian information criterion: background, derivation, and applications. Wiley Interdiscp Rev Comput Stat. 2012;4(2):199-203.
24. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028-3035.
25. Pittman DG, Tao Z, Eisenberg ES, Pendergrass M. Adherence to antihypertensive medications is associated with fewer cardiovascular related hospitalizations and ED visits in patients 65 and older. In: Program and abstracts of the Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2012 Scientific Sessions, May 9-11, 2012; Atlanta, GA. Circ Cardiovasc Qual Outcomes. 2012; 5(Suppl 3):Abstract A47.
26. Chan SA, Hussain F, Lawson LG, Ormerod AD. Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities. J Dermatolog Treat. 2013;24(1):64-69.
27. Sandoval LF, Huang KE, Feldman SR. Adherence to ustekinumab in psoriasis patients. J Drugs Dermatol. 2013;12(10):1090-1092.
28. Devaux S, Castela A, Archier E, etal. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26 Suppl 3:61-67.
29. Barber N, Parsons J, Clifford S, Darracott R, Horne R. Patients' problems with new medication for chronic conditions. Qual Saf Health Care. 2004;13(3):172-175.